Mylan Heather Bresch announced her planned retirement from the company in 2020.
The 28-year veteran of the company said she’s planning to step aside as Mylan is joining forces with Pfizer’s Upjohn business, the companies said Monday. Once the deal closes in mid-2020, Bresch said she will retire. Mylan’s executive chairman Robert Coury will stay on in the same role, as will President Rajiv Malik, who’s been named in a generics price-fixing suit brought by state attorneys general. Bresch is set to collect about $37.6 million with the change in leadership, per a Mylan proxy filing. She’s been among the highest-paid CEOs across pharma in years past, although she didn’t make the top 20 in 2018. FiercePharma
Date: August 7, 2019
Source: Fierce Biotech
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
